The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
2010 · Cancer Cell · 1,966 citations
https://doi.org/10.1016/j.ccr.2010.01.020
D
David R. Wise
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
112
Papers
9.0K
Citations
17
h-index
30
i10-index
David R. Wise is an academic researcher from NYU Langone Health. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Radiopharmaceutical Chemistry and Applications & Prostate Cancer Diagnosis and Treatment. The author has an h-index of 17, co-authored 96 publications.
ORCID: 0000-0003-3419-4723Papers by this author
worksATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation
2012 · Cancer Cell · 379 citations
https://doi.org/10.1016/j.ccr.2012.09.021
Hypoxic Reactive Oxygen Species Regulate the Integrated Stress Response and Cell Survival
2008 · Journal of Biological Chemistry · 203 citations
https://doi.org/10.1074/jbc.m805056200
Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
2023 · Journal of Clinical Oncology · 27 citations
https://doi.org/10.1200/jco.2023.41.6_suppl.154
Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC).
2023 · Journal of Clinical Oncology · 17 citations
https://doi.org/10.1200/jco.2023.41.6_suppl.153
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial
2023 · European Urology Oncology · 17 citations
https://doi.org/10.1016/j.euo.2023.07.008
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat